Policy & Regulation: Page 24
-
PharmaVoice Team/PharmaVoice
Pharma 3.0 Next Steps
Robin Robinson Pharma Expands Disease Categories of 3.0 Efforts Between 2006 and 2009, 24% of Pharma 3.0 initiatives focused first on diabetes and metabolics. In 2010, oncology moved to the top with 15% of the year’s initiatives, and diabetes and metabolics tied for second with immunoscience/...
By PharmaVoice Team • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Alex AZAR Maria CROWE Dave RICKS Lilly Makes Management Changes Lilly has announced a number of key management appointments. Alex Azar has been promoted to president of Lilly USA, the company’s...
By Carolyn Gretton • Dec. 22, 2011 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Tools of the Trade
New electronic and web-based applications, sites, and technologies By Carolyn Gretton ImpactRx Adds Tablet Detailing to Analytics Offerings Trend: Growing physician adoption of tablet computers is prompting pharma brand teams to design and execute messaging strategies that more effectively employ...
By Carolyn Gretton • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Building a Culture of Innovation
Pharmaceutical R&D is under pressure to counter rising costs, depleted pipelines, and impending patent expiries. The industry is facing not only a productivity crisis, but also a crisis in innovation. Industry analysts say many pharmaceutical and biopharma companies are turning their focus aw...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
C-Suite: Executive Insights
CEOs, presidents, and executive management team members from across the industry — pharmaceutical, biotechnology, and service companies — discuss the most crucial factors driving change in the industry, as well as their strategies for meeting the challenges of business in the coming years. Jed Be...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
What's Ahead for 2012
Our readers identified the top trends and game changers they expect to define the various industry sectors in the coming year. John Blakeley Executive VP and Chief Commercial Officer ERT, a clinical research service provider that assesses the safety of newly developed drugs by major pharmaceutica...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
On the Calendar
Industry Events and Conferences, including SPECIAL DISCOUNTS Coming ATTRACTIONS Attendees interested in maximizing their clinical trial performance by bridging the gap between identifying and implementing metrics, learning about best practices on processing data and on-site performance to improve...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Greg IRACE Anne WHITAKER Sanofi Shifts U.S. Leadership Sanofi has named Greg Irace senior VP, global services. Mr. Irace leads the global information systems function and is responsible for shared support functions across all Sanofi businesses in North America. He also plays a...
By PharmaVoice Team • Sept. 27, 2011 -
PharmaVoice Team/PharmaVoice
2011 PharmaVOICE 100 - Who's on the List by Section
The Commanders & Chiefs Frank Baldino Jr., Ph.D. Cephalon Inc. Donna Beardsworth. Beardsworth Group Calep A. (Joe) Boyd III MCS Healthcare Public Relations Randall Carpenter, M.D. Seaside Therapeutics N. Anthony Coles, M.D. Onyx Pharmaceuticals B. Reid Connolly evoke interaction Donna Cryer C...
By PharmaVoice Team • July 26, 2011 -
PharmaVoice Team/PharmaVoice
2011 PharmaVOICE 100 - Who's on the List by Company
Acorda Therapeutics Andrew Blight, Ph.D. ACT Biotech Inc. Ali Fattaey, Ph.D. Acucela Inc. Ryo Kubota, M.D., Ph.D. Alliance Healthcare Information LLC Mary Anne Greenberg Almac Group Sir Allen McClay The Avoca Group Inc. Patricia Leuchten AXON US Mario Nacinovich Beardsworth Group Donna Beardswort...
By PharmaVoice Team • July 26, 2011 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Taking Inspiration to the Next Level This is our favorite issue of the year, and we hope it’s yours too. It has been a joy and a privilege to have had a chance to get to know this year’s PharmaVOICE 100. They certainly illustrate what it means to think bigger, do more, and lead with passion and i...
By Taren Grom • July 26, 2011 -
PharmaVoice Team/PharmaVoice
Changing Oncology Regulations
Developing oncology therapies can be complex. These products often have a tough time making it to the market. In fact, a study released in February by the Biotechnology Industry Organization and BioMedTracker shows that oncology products had the lowest Phase III success rate among seven therapeut...
By Denise Myshko • May 24, 2011 -
PharmaVoice Team/PharmaVoice
Navigating the New Communications Landscape
The ways patients seek and share information—both in and out of the doctor’s office—are undergoing radical change. From the rise of the Internet to the explosion of social media to the growing patient demand for active participation in treatment decisions, a multitude of forces are converging to ...
By Chris DeAngelis • April 25, 2011 -
PharmaVoice Team/PharmaVoice
Be Successful in the New World of Accountable Care Organizations
In a few months, there will be a fundamental shift in how some Medicare providers operate with the beginning of the Medicare Shared Savings Program. In January 2012, Accountable Care Organizations (ACOs) identified by the U.S. secretary of Health and Human Resources will emerge that practice diff...
By Keith Mandia Senior Director • April 25, 2011 -
PharmaVoice Team/PharmaVoice
mHealth: Pharma's Next Blockbuster
The practice of mobile health, or mHealth as it is now known, has been around for decades. The first initiatives were designed to provide greater healthcare access to remote populations, mostly in developing countries. This trend continues and grows daily, providing many patients with a higher qu...
By PharmaVoice Team • April 25, 2011 -
PharmaVoice Team/PharmaVoice
The Era of Biosimilars
Although healthcare reform paved the way for a regulatory pathway for biosimilars, the biopharmaceutical industry is facing a world of uncertainty as developers and regulators navigate their way through this shifting landscape. Biosimilar Defined » A “biosimilar" is a biological product that i...
By Denise Myshko • March 29, 2011 -
PharmaVoice Team/PharmaVoice
What's New
The INSTITUTE OF CONTINUING HEALTHCARE EDUCATION and healthcare simulation technology developer HUMAN CONDITION HEALTH (HCH) are working together to develop learner-driven continuing medical education (CME) for healthcare professionals with a long-term focus on improving patient outcomes. Throug...
By PharmaVoice Team • March 28, 2011 -
PharmaVoice Team/PharmaVoice
Thought Leaders
Ryan Abbate. President, Pacific Communications, a healthcare communications agency that offers strategic and tactical communications solutions. For more information, visit pacific-com.com. Edward Abrahams, Ph.D. President,The Personalized Medicine Coalition, which brings together the academ...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
The End of the Arms Race
After more than a decade of crowding physicians’ offices with as many sales reps who would fit, the pendulum has swung dramatically in the other direction. The industry’s field ranks have been reduced dramatically, and now sales reps are crowding unemployment offices. Not just a Hired Gun Terren...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
Everyone is Watching
The advent and growth of federal and state compliance regulations and the monitoring of those regulations have absolutely been game changers in the life-sciences industry over the last 10 years, says Peter Sandford, executive VP of NXLevel Solutions, a developer of technology-delivered learning a...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
The Patent Cliff
As companies look to fill the estimated $16 billion in annual revenue expected to be lost to generics over the next five years alone, they must become more adept at life-cycle management, pursuing viable reimbursement strategies, and developing evidence-based communications. If it seems as thoug...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
R&D Innovation: The Key to Long-Term Success
When the scientific discoveries and pipeline-building process of many successful biotechs are layered together, the results are likely to be dramatic. Experts predict there will be a number of game-changing product candidates in development in the next decade. “We view ourselves as part of the ‘m...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
Agility: Key to Agency Success in the Future
For anybody involved in healthcare advertising, on the agency as well as the client side, the last decade has been marked by myriad changes and market factors that have impacted all aspects of the business. Client mergers and acquisitions, heightened regulatory scrutiny of messaging, more messagi...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Dr. Robert CUDDIHY Sanofi-Aventis Adds to Diabetes Team Sanofi-Aventis U.S. has appointed Robert Cuddihy, M.D., VP, medical diabetes head in the U.S. Dr. Cuddihy is responsible for developing and executing the U.S. medical affairs strategy for Sanofi-Aventis’s diabetes divisio...
By PharmaVoice Team • March 3, 2011 -
PharmaVoice Team/PharmaVoice
On the Calendar
March 21-22 BioConference Live: Life Sciences PharmaVOICE is exhibiting at this event. BioConference Live, bioconferencelive.com March 21-23 Digital Marketing & Communications for Canadian Pharma Toronto PharmaVOICE subscribers receive a $200 discount; register using keycode PharmaVOICE Adva...
By PharmaVoice Team • March 3, 2011
Previous
